Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Operating Profit Margin
since 2005

Microsoft Excel

Paying user area

Try for free

Biogen Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Biogen Inc., operating profit margin, long-term trends, calculation

Microsoft Excel
Operating profit margin = 100 × Income from operations1 ÷ Revenues1
Dec 31, 2021 = 100 × ÷
Dec 31, 2020 = 100 × ÷
Dec 31, 2019 = 100 × ÷
Dec 31, 2018 = 100 × ÷
Dec 31, 2017 = 100 × ÷
Dec 31, 2016 = 100 × ÷
Dec 31, 2015 = 100 × ÷
Dec 31, 2014 = 100 × ÷
Dec 31, 2013 = 100 × ÷
Dec 31, 2012 = 100 × ÷
Dec 31, 2011 = 100 × ÷
Dec 31, 2010 = 100 × ÷
Dec 31, 2009 = 100 × ÷
Dec 31, 2008 = 100 × ÷
Dec 31, 2007 = 100 × ÷
Dec 31, 2006 = 100 × ÷
Dec 31, 2005 = 100 × ÷

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands

Income from operations
There is a clear upward trend in income from operations from 2005 through 2019, rising from approximately 236 million US dollars to over 7 billion US dollars. This indicates substantial growth over this 14-year period. However, a notable decline is observed in 2020 and 2021, with income decreasing to about 4.55 billion and then further down to roughly 2.84 billion US dollars, suggesting operational challenges or market changes impacting profitability during these two years.
Revenues
Revenues show consistent growth from 2005, starting at approximately 2.42 billion US dollars and reaching a peak in 2019 of nearly 14.38 billion US dollars. This growth trend reflects an expanding business scale or increased market demand. Nevertheless, similar to income from operations, revenues decrease in 2020 and 2021 to about 13.45 billion and then 10.98 billion US dollars, indicating a downturn or contraction in business volumes or sales during the last two years analyzed.
Operating profit margin
Operating profit margin exhibits a positive trend overall, improving significantly from 9.74% in 2005 to a peak of approximately 48.98% in 2019. This suggests improved operational efficiency and profitability relative to revenues over this period. In 2020 and 2021, the margin declines to 33.84% and then 25.87%, which aligns with the decreases observed in income and revenues, indicating that not only did absolute profits fall, but profitability relative to sales also diminished, potentially due to increased costs or pricing pressures.

Comparison to Competitors

Biogen Inc., operating profit margin, long-term trends, comparison to competitors

Microsoft Excel
Biogen Inc. AbbVie Inc. Amgen Inc. Danaher Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Dec 31, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 31, 2008
Dec 31, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).